BioSpace News Archive

Business

vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program

Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. vTv Therapeutics will also receive shares of Reneo Pharmaceuticals’ common stock.

December 21, 2017

·

4 min read

Biotech Bay

ABIVAX to Participate in ‘Corporate Access’ Event in San Francisco, January 8 - 10, 2018

Abivax today announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

December 21, 2017

·

1 min read

Business

IBBL Release: Biobank on the Move

At the end of November, IBBL moved its staff, its equipment and its 500,000 samples from Luxembourg City to Dudelange.

December 21, 2017

·

3 min read

Business

NAI Appoints New VP, Global Supply Management

NAI, a leading manufacturer of global connectivity solutions for high performance systems used in the industrial technology, telecom, data and medical industries, announces the appointment of Eric Emley to the position of Vice President of Global Supply Management.

December 21, 2017

·

3 min read

Policy

Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency

Emmaus Life Sciences announced today that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the company’s pediatric investigation plan (PIP) for its treatment of sickle cell disease.

December 21, 2017

·

3 min read

FDA

QView Medical Inc. Announces FDA PMA Approval for QVCAD for the GE Invenia™ 3D Automated Breast Ultrasound System (“ABUS”)

QView Medical is pleased to announce FDA approval for QVCAD to be used with the GE Invenia™ ABUS in breast screening for asymptomatic dense breasted women whose mammogram was negative.

December 21, 2017

·

4 min read

FDA

EU Follows US and Approves Chugai’s ALK Inhibitor “Alecensa®" as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical Co., Ltd announced today that F. Hoffmann-La Roche Ltd. obtained approval from the European Commission, for Alecensa® as monotherapy indicated for “the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)”.

December 21, 2017

·

5 min read

Drug Development

Biohaven Enrolls First Patient in Pivotal Trial of Trigriluzole in Patients With Obsessive-Compulsive Disorder

Biohaven today announced that it has commenced enrollment in its Phase 2/3 clinical trial assessing the efficacy and safety of trigriluzole in patients with OCD.

December 21, 2017

·

5 min read

Business

Denis DELVAL is Appointed CEO of LFB SA

Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures.

December 21, 2017

·

2 min read

Drug Development

Frequency Therapeutics’ First-in-Human Safety Study of FX-322 for Hearing Restoration Achieves All Endpoints

Frequency Therapeutics today announced the successful completion of a first-in-human study of FX-322, the company’s lead PCA candidate for hearing restoration.

December 21, 2017

·

6 min read